CC
ADMA icon

Clearline Capital’s ADMA Biologics ADMA Stock Holding History

Clearline Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
1,334,725
+778,671
+140% +$7.1M 0.67% 44
2026
Q1 		$5.01M Buy
+556,054
New +$8.78M 0.26% 69
2022
Q4 		– Sell
-2,496,297
Closed -$6.07M – 121
2022
Q3 		$6.07M Sell
2,496,297
-421,963
-14% -$1.01M 0.73% 37
2022
Q2 		$5.78M Sell
2,918,260
-2,219,597
-43% -$4.37M 0.75% 35
2022
Q1 		$9.4M Sell
5,137,857
-1,212,837
-19% -$1.89M 1.08% 30
2021
Q4 		$8.95M Buy
6,350,694
+5,603,249
+750% +$7.37M 0.98% 32
2021
Q3 		$845K Sell
747,445
-175,072
-19% -$245K 0.08% 107
2021
Q2 		$1.48M Buy
922,517
+574,439
+165% +$1.01M 0.22% 78
2021
Q1 		$613K Buy
+348,078
New +$797K 0.08% 85

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Clearline Capital's ADMA Position: Q2 2026 in Review

Clearline Capital increased its ADMA Biologics (ADMA) stake by 140% in Q2 2026, buying an estimated $7.1M and bringing the position to 1,334,725 shares worth $11.2M. The position accounts for 0.67% of the portfolio, ranked #44.

Clearline Capital first reported a position in ADMA in Q1 2021 and has held it in 9 quarters since. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Clearline Capital held 1,334,725 shares of ADMA Biologics worth $11.2M as of Q2 2026.
  • Clearline Capital bought 778,671 ADMA Biologics shares in Q2 2026, an estimated $7.1M.
  • ADMA Biologics made up 0.67% of Clearline Capital's portfolio in Q2 2026, its #44 holding.
  • Clearline Capital first reported a position in ADMA Biologics in Q1 2021 and has held it in 9 quarters since.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Clearline Capital's 13F filing for Q2 2026, filed 14 Aug 2026.